SLC16A1 and neuroblastoma: Aberrant expression such as, upregulation of MCT1 and MCT4 has been reported in a large number of tumors (e.g., neuroblastomas, high-grade gliomas, carcinomas of renal cells, breast epithelium, colorectal and squamous tissues, and cervical and lung cancers) where expression is correlated to poor outcomes.